Concordia Healthcare Corp

Concordia Healthcare Corp
Public company
Traded as TSX: CXR
Industry Pharmaceutical industry
Founded 2012
Headquarters Canada
Key people
 Mark L. Thompson (President & CEO)
Leith Tessy (CFO)
Wayne Kreppner (COO)
Products Kapvay, Zonegran, Donnatal
Revenue Increase $122 million (2014)[1]
Website

Concordia Healthcare Corp is a publicly traded pharmaceutical company based in Canada. The company focuses on Attention-Deficit Hyperactivity Disorder, cancer and asthma. The company was founded in December 2012 [2] and has since pursued a corporate strategy of growth-through acquisition, much like fellow Canadian company Valeant Pharmaceuticals. The company also focuses on acquiring legacy pharmaceutical compounds which are usually off patent.[3] Concordia Healthcare Corp currently comprises three companies: Concordia Pharmaceuticals Inc., Pinnacle Biologics Inc., and Complete Medical Homecare Inc.[4]

Corporate history

2013

In May the company acquired Pediatric products (Kapvay, Orapred ODT & OS) from Shionogi Inc.[5][6] In October the company acquired Complete Medical Homecare,[7] then in December the company completed the takeover of Mercari Acquisition Corp.[8] as well as Pinnacle Biologics Inc,[9] and began trading on the Toronro stock exchange.

2014

In January the company completed a five year exclusive distribution deal with Lachlan Pharma Holdings to distribute Ulesfia United States.[10] In March, the company entered into a definitive agreement to acquire the irritable bowel syndrome drug, Donnatal, from Revive Pharmaceuticals for $200 million and 4,605,833 common shares of company stock.[11] The deal was completed in May. In September the company entered into its first collaboration with Orphan Canada.[12] In the same month the company announced it would acquire Zonegran in the United States and Puerto Rico, for $90 million.[13]

2015

In March the company announced its largest acquisition to date when it agreed to buy the majority of assets of Covis Pharma Sarl and Covis Injectables Sarl for $1.2 billion in cash.[14][15]

References

  1. ↑ "Concordia Healthcare Announces Fourth Quarter and Fiscal 2014 Results". concordiarx.com.
  2. ↑ "Milestones". concordiarx.com.
  3. ↑ Stefanie Batcho-Lino. "Valeant Clone Concordia Top Canada Stock as CEO Eyes Deal". Bloomberg.com.
  4. ↑ "Overview - Concordia Healthcare Corp.". concordiarx.com.
  5. ↑ http://www.shionogi.co.jp/en/company/news/2013/pmrltj0000001q6t-att/e_130508.pdf
  6. ↑ "Concordia acquires several pediatric products from Shionogi". pharmamedtechbi.com.
  7. ↑ "Complete Medical Homecare, Inc. And Midwest Medical Services, Inc. And Global Medical Direct LLC: Private Company Information - Businessweek". Businessweek.com.
  8. ↑ "Mercari Acquisition Corp. - Mercari Acquisition Corp. announces proposed qualifying transaction with Concordia Healthcare Inc.". newswire.ca.
  9. ↑ Concordia Healthcare Corp. (24 December 2013). "Concordia Healthcare Corp. Announces Acquisition Of Pinnacle Biologics, Inc.". prnewswire.com.
  10. ↑ Concordia Healthcare Corp. (6 January 2014). "Concordia Healthcare Corp. announces Exclusive Distribution Agreement for Ulesfia® with Lachlan Pharma Holdings". prnewswire.com.
  11. ↑ Concordia Healthcare Corp. (20 March 2014). "Concordia Healthcare Announces Agreement to Acquire Donnatal®". prnewswire.com.
  12. ↑ "Concordia Healthcare Corp. enters into collaboration agreement with Orphan Canada". Yahoo Finance. 2 September 2014.
  13. ↑ "Concordia Healthcare Corp. - Concordia Healthcare Announces Agreement to Acquire Zonegran® in the United States and Puerto Rico". newswire.ca.
  14. ↑ Scott Deveau. "Concordia Agrees to Buy Covis Health Assets for $1.2 Billion". Bloomberg.com.
  15. ↑ Judy McKinnon (9 March 2015). "Concordia Healthcare to Buy Some Assets of Covis Pharma". WSJ.